847617-82-7Relevant academic research and scientific papers
Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors
Kühne, Holger,Obst-Sander, Ulrike,Kuhn, Bernd,Conte, Aurelia,Ceccarelli, Simona M.,Neidhart, Werner,Rudolph, Markus G.,Ottaviani, Giorgio,Gasser, Rodolfo,So, Sung-Sau,Li, Shirley,Zhang, Xiaolei,Gao, Lin,Myers, Michael
, p. 5092 - 5097 (2016/10/05)
Dual inhibition of fatty acid binding proteins 4 and 5 (FABP4 and FABP5) is expected to provide beneficial effects on a number of metabolic parameters such as insulin sensitivity and blood glucose levels and should protect against atherosclerosis. Starting from a FABP4 selective focused screening hit, biostructure information was used to modulate the selectivity profile in the desired way and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. With very good pharmacokinetic properties and no major safety alerts, compound 12 was identified as a suitable tool compound for further in vivo investigations.
NEW ARYL-QUINOLINE DERIVATIVES
-
Page/Page column 71; 125-126, (2013/05/22)
The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4 R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds.
ARYL-QUINOLINE DERIVATIVES
-
Paragraph 0462; 0741; 0742, (2013/05/21)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.
